Sleep Medications: Types, How They Work, and When to Use Them

Sleep medications are among the most commonly prescribed and purchased drug categories globally. Yet many patients — and prescribers — lack a clear framework for when pharmacological intervention is appropriate, which drug class to consider, and how to limit the risks of dependence and residual impairment. This guide covers the evidence honestly.

The Medication-vs-CBT-I Decision

For chronic insomnia disorder, the American College of Physicians (2016 guideline, reaffirmed 2021) explicitly recommends cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment over medication. Head-to-head trials consistently show CBT-I produces equivalent or superior short-term outcomes to medication and significantly better long-term outcomes — with no side effects, no rebound insomnia, and sustained improvements persisting years after treatment ends.

Medication is appropriate as a short-term bridge (while awaiting CBT-I access), during acute life stressors, for specific clinical presentations that do not respond adequately to behavioral treatment, or when comorbid conditions warrant pharmacological management of both the underlying condition and insomnia. Sleep therapy options including CBT-I are more widely accessible now via digital programs and therapist directories.

Over-the-Counter Sleep Medications

Antihistamines (Diphenhydramine, Doxylamine)

The active ingredient in most OTC sleep aids — Benadryl, ZzzQuil, Unisom SleepTabs (diphenhydramine) and Unisom SleepMelts (doxylamine) — is a first-generation antihistamine. Sedation is a side effect, not the primary mechanism. Tolerance develops within days to a week, rendering them ineffective for ongoing insomnia. They have significant anticholinergic effects: next-morning grogginess, dry mouth, urinary retention (a significant concern in older men), and cognitive blunting. Long-term use of anticholinergic drugs is associated with increased dementia risk in observational studies, though causality is debated. Best limited to occasional use only.

Melatonin

Melatonin is a neurohormone secreted by the pineal gland in response to darkness. Exogenous melatonin is most effective for circadian phase disorders: reducing jet lag symptoms, advancing sleep timing in delayed sleep phase disorder, and helping shift workers transition sleep schedules. For general insomnia, effects are modest — a meta-analysis found melatonin reduces sleep onset by approximately 7 minutes on average. Effective doses are lower than most sold products: 0.3 to 1 mg. Standard 5 to 10 mg OTC doses likely exceed physiological saturation and may cause morning suppression of endogenous production.

Prescription Sleep Medications

Z-Drugs (Non-Benzodiazepine GABA-A Agonists)

Zolpidem (Ambien), eszopiclone (Lunesta), and zaleplon (Sonata) work by potentiating GABA — the brain's primary inhibitory neurotransmitter — at the GABA-A receptor complex. They reduce sleep latency and increase total sleep time. The FDA has issued black box warnings for next-morning impairment (particularly with extended-release zolpidem), complex sleep behaviors (sleepwalking, sleep-eating, sleep-driving), and psychological dependence. The FDA reduced recommended zolpidem doses in 2013 after data showed significant next-morning driving impairment, particularly in women.

Benzodiazepines

Triazolam (Halcion), temazepam (Restoril), flurazepam, and quazepam are FDA-approved for insomnia from this class. They share the GABA-A mechanism with Z-drugs but bind non-selectively across receptor subtypes, producing greater anxiolytic and muscle relaxant effects — and greater dependence liability. Physical dependence can develop within 2 to 4 weeks of nightly use. Withdrawal syndrome includes rebound insomnia, anxiety, and in severe cases, seizures. These are considered second-line agents for insomnia by current guidelines.

Orexin Receptor Antagonists

Suvorexant (Belsomra) and lemborexant (Dayvigo) represent a mechanistically distinct approach. Rather than sedating, they block orexin (hypocretin) — the neuropeptide that maintains wakefulness. The result is more natural sleep initiation with a different side effect profile. Next-day somnolence remains the primary complaint. Abuse potential is classified as Schedule IV (same as benzodiazepines) but clinical dependence appears lower. Approved for both sleep onset and maintenance insomnia in adults.

Low-Dose Doxepin (Silenor)

At doses of 3 to 6 mg — far below antidepressant doses — doxepin selectively antagonizes histamine H1 receptors to maintain sleep. Its primary indication is sleep maintenance insomnia (waking in the second half of the night). It carries minimal next-morning impairment at approved doses and no significant dependence risk. FDA-approved for sleep maintenance insomnia in adults and the elderly.

Trazodone

Widely prescribed off-label for insomnia (it has no FDA indication for insomnia), trazodone is an antidepressant whose sedating properties at low doses (25 to 100 mg) are used clinically. Evidence specifically for insomnia is limited — most trials are short-term and underpowered. It is commonly used because it has no scheduled controlled substance status and perceived dependence risk is low. Side effects include next-morning sedation, orthostatic hypotension, and in rare cases priapism.

Special Populations and Cautions

The 2019 American Geriatrics Society Beers Criteria explicitly lists benzodiazepines and Z-drugs as potentially inappropriate for adults 65 and older due to elevated fall risk, hip fracture risk, and cognitive impairment. Pregnancy and breastfeeding require consultation — most sleep medications lack adequate safety data. Medical comorbidities including liver disease, sleep apnea, and respiratory conditions affect drug selection significantly.

The Role of the Sleep Environment

Medication works within an environment. A mattress causing repeated awakenings from back pain, overheating, or motion transfer from a partner creates physical arousal that reduces medication effectiveness and inflates the apparent dose needed. Addressing physical sleep environment issues in parallel with pharmacological management — or before initiating medication — is good clinical practice.

Frequently Asked Questions

Is it safe to take sleep medication every night?

It depends on the drug class. Melatonin and low-dose doxepin have reasonable short-term safety profiles. Benzodiazepines and Z-drugs (zolpidem, eszopiclone) carry tolerance and dependence risks with nightly use beyond 2 to 4 weeks. The American College of Physicians recommends CBT-I as the first-line treatment for chronic insomnia, with medication as a short-term bridge or adjunct rather than indefinite monotherapy.

What is the difference between Ambien and Lunesta?

Both are Z-drugs (non-benzodiazepine GABA-A receptor agonists) approved for insomnia. Zolpidem (Ambien) has a shorter half-life and is FDA-approved for sleep onset. Eszopiclone (Lunesta) has a longer half-life (approximately 6 hours) and is approved for both sleep onset and maintenance. Eszopiclone is the only Z-drug approved for longer-term nightly use. Both carry next-morning impairment risks.

Can sleep medications make insomnia worse?

Yes — this is called rebound insomnia. When benzodiazepines or Z-drugs are discontinued after regular use, sleep often worsens temporarily as the brain upregulates arousal systems previously suppressed by the drug. This is one reason abrupt discontinuation is not recommended and why gradual tapering under medical supervision is the standard approach.

What is suvorexant and how is it different?

Suvorexant (Belsomra) and lemborexant (Dayvigo) are orexin receptor antagonists — a newer mechanism class. Rather than sedating the brain, they block the wake-promoting signal of orexin (hypocretin). This mechanism produces a more natural sleep transition and carries less next-day impairment at approved doses. They are associated with lower dependence risk than Z-drugs and are approved for both sleep onset and maintenance insomnia.

Is melatonin a sleeping pill?

Melatonin is a hormone, not a sedative. It signals biological night to the circadian system but does not produce sleep directly. It is most effective for circadian disorders — jet lag, delayed sleep phase, shift work — and for sleep onset insomnia with a significant circadian component. Evidence for maintenance insomnia (staying asleep) is weak. Appropriate doses are lower than most OTC products contain: 0.3 to 1 mg is often sufficient; doses above 5 mg are rarely more effective and may cause morning grogginess.